Gemifloxacin (Factive®) is a fourth-generation, naphthyridine-based fluoroquinolone antibiotic that demonstrates potent, broad-spectrum antibacterial activity against respiratory pathogens. Since its approval by the United States Food and Drug Administration (FDA) in April 2003, gemifloxacin has occupied a distinct clinical niche due to its exceptional potency against drug-resistant Streptococcus pneumoniae, comprehensive coverage of atypical respiratory pathogens, and favorable pharmacokinetic profile enabling once-daily oral administration.
Kumar et al. (Wed,) studied this question.